We're creating a community of researchers through our new program, Tempus+. Participants, including UCLA Jonsson Comprehensive Cancer Center, RUSH, & UNC Lineberger, can use our platform to identify patterns and insights, define and test their hypotheses, and more. Learn more: tempus.co/3DfA1gM

#NEWS : We're proud to welcome Dr. Kate Sasser as our new CSO! She will be focused on utilizing cutting-edge science & the power of multimodal data to bring personalized medicine solutions to life science collaborators, physicians, and patients. More here: tempus.co/3SOGEwp

We're honored that Gordon shared his story with us. After 4 surgeries & 4 lines of treatment, he was sequenced by Tempus after seeking a 2nd opinion. As a result, he started a new treatment plan that changed the course of his journey. Hear his full story: tempus.co/3sapMFs

#NEWS : Together with GSK, we are leveraging data and AI to improve oncology drug targets and #clinicaltrial design to provide patients with more personalized treatment faster. Read more here: tempus.co/3MFjt64

In honor of #BreastCancerAwarenessMonth , we’re sharing the treatment journey of one of our very own. Kimberly Yeatts, VP of Clinical Lab Operations, was diagnosed with breast cancer while building our lab team here at Tempus. Hear her story: tempus.co/3enT1Bl

It’s #WorldMentaHealth Day and we want to take a moment to reflect on the strides we've made in addressing #mentalhealth . We still have more to accomplish in helping physicians deliver personalized patient care and we're excited to see what this community can achieve together.

#NEWS : We’re collaborating with Kartos Therapeutics to develop a #CDx in support of its Phase II study of navtemadlin. Developed on our xT platform, the CDx will be used to help identify patients w/ Merkel cell carcinoma that may be eligible for the study. tempus.co/3MbPUZC

#ESMO22 was characterized by a generation of new evidence on therapeutic outcomes in biomarker-defined subgroups of patients. Our SVP of Medical Affairs, Calvin Chao, MD, distilled some of the research he found the most compelling this year here: tempus.co/3C931Gd

On 10/9 at 1:30pm CT, we’re hosting a live product theater at #CAP22 w/ our own Dr. Brett Mahon. Join us to learn how our developing, AI-driven biomarker technology can bring insights to your testing. Or discover more about our digital pathology work here: tempus.co/3N0GzUy

This survey demonstrated wider adoption of #RWE applications, w/ companies using RWE to understand disease progression, more precisely find the patient populations that can benefit from certain clinical trials, & more. We can help support RWE-enabled R&D tempus.co/3PiCOuq

It is #HispanicHeritageMonth , and our HOLA ERG is hosting celebrations and discussions around history, food, community, and more! We recently spoke to Mariela Hernandez on our Therapies team, who shared what being Hispanic means to her.

Whole transcriptome RNA sequencing, & therefore analysis of translocations/fusion genes, may provide more results than just DNA-only sequencing. Dr. Cohen co-authored a recent Tempus study that demonstrated the value of sequencing both DNA & RNA. Read more tempus.co/3qVkRri

#NEWS : We're collaborating with Children’s Oncology Group to support their Pediatric MATCH Screening Trial, providing pediatric cancer patients with increased access to genomic sequencing - a critical component for physicians in personalizing care. Read more: tempus.co/3xD41kw

1/ A quick 🧵re: practical impact of DPYD genotyping in treating patients with GI cancer.

The patient (shared with permission) is a 50s M with metastatic colon cancer, found to have DPYD *2A in pretreatment testing.

Our Medical Affairs team joined academic experts to assess the efficacy of #PGx clinical trials. Patients who received PGx-guided therapy were 1.41x more likely to see improvement from treatment compared to those that were treat-as-usual. Read the abstract tempus.co/3xuK3s5

Thank you Steve Case! Honored to have Tempus and our Founder & CEO Eric Lefkofsky included in the #RiseOfRestBook .

This study supports the clinical use of tumor-normal #NGS testing, stating “with the advent of tumor-normal testing, more clinically actionable germline findings are being discovered across cancer types…” Learn about the benefits of tumor-normal testing: tempus.co/3qZm7L6

On 9/29, our SVP of External Affairs, Lauren Silvis, is chairing a Clinical Biomarkers & World CDx panel on data-driven #CDx development. Leaders from Pfizer, AstraZeneca and Kartos will discuss how multimodal data can optimize CDx strategies. Learn about our CDx work: tempus.co/3qyf4HM

Glad to see the continued advancement of the #cancermoonshot initiative. There is still so much work to be done, and we look forward to working with the the oncology community to achieve our goals.